Intuitive Surgical, Inc. ISRG
- Market cap
- $140.7B
- P/E
- 45.8×
Follow ISRG
Intuitive Surgical, Inc. (ISRG) EV/EBITDA
As of 25 September 2026, Intuitive Surgical, Inc. (ISRG) trades at a EV/EBITDA of 32.5×. Over the past ten years it has ranged from 18.6× (October 2015) to 74.8× (November 2024); the current reading is higher than 26% of that period. That is above the Medical Instruments & Supplies industry median of 16.1× and above the Healthcare sector median of 10.4×.
EV/EBITDA, daily
Annual
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 54.2× | (14.94%) |
| FY2024 | 63.7× | 27.42% |
| FY2023 | 50.0× | 8.91% |
| FY2022 | 45.9× | (19.77%) |
| FY2021 | 57.2× | (15.25%) |
| FY2020 | 67.5× | 65.14% |
| FY2019 | 40.9× | 5.98% |
| FY2018 | 38.6× | 13.19% |
| FY2017 | 34.1× | 62.68% |
| FY2016 | 20.9× | (4.17%) |
Quarterly
| Period | EV/EBITDA | Change |
|---|---|---|
| Jun 2026 | 31.9× | (20.70%) |
| Mar 2026 | 40.2× | (25.78%) |
| Dec 2025 | 54.2× | 20.36% |
| Sep 2025 | 45.0× | (24.45%) |
| 42 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| MDLN Medline Inc. compare | 3.9× |
| SOLV Solventum Corporation compare | 7.9× |
| ALC Alcon compare | 12.7× |
| BDX Becton, Dickinson and Company compare | 13.3× |
| BAX Baxter International Inc. compare | 13.3× |
| RMD ResMed Inc. compare | 14.7× |
| WST West Pharmaceutical Services, Inc. compare | 30.2× |
| ISRG Intuitive Surgical, Inc. | 32.5× |
| RGEN Repligen Corporation compare | 65.3× |
| Medical Instruments & Supplies industry median | 16.1× |
| Healthcare sector median | 10.4× |
| Market median | 11.0× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on ISRG
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement